DOCSLIB.ORG

Cost Analysis and Safety Comparison of Cisatracurium and Atracurium in Patients Undergoing General Anesthesia

Total Page：16

File Type：pdf, Size：1020Kb

Download full-text PDF Read full-text
Cost Analysis and Safety Comparison of Cisatracurium and Atracurium in Patients Undergoing General Anesthesia Eur opean Rev iew for Med ical and Pharmacol ogical Sci ences 2013; 17: 447-450 Cost analysis and safety comparison of Cisatracurium and Atracurium in patients undergoing general anesthesia A. MOVAFEGH, S. AMINI*, H. SHARIFNIA, H. TORKAMANDI*, A. HAYATSHAHI*, M. JAVADI* Intensive Care Unit, and *Pharmaceutical Care Department; Dr. Shariati Hospital, Tehran University of Medical Sciences, Tehran, Iran Abstract. – BACKGROUND : Non-depolarizing Introduction neuromuscular blocking agents (NMB) differ in pharmacokinetic and pharmacodynamic parame - The introduction of neuromuscular blocking ters. An anesthesiologist according to these simi - larities and differences is able to choose the least agents in 1942 into anesthetic practice was an im - costly one if the same safety profile and same clin - portant development. Non-depolarizing NMB ical benefit achieved with the different alternatives. agents differ in the onset of action, duration of ac - AIM: The main objective of this study is to eval - tion, metabolic route, potency, adverse effects and uate the economic and adverse drug reactions cost. An anesthesiologist is able to choose NMB prevalence and differences between cisatracurium drugs according to these similarities and differ - and atracurium the two non-depolarizing NMB 1,2 drugs, which are widely used in adult patients un - ences . Atracurium and Cisatracurium are two dergoing surgery with general anesthesia in a non-depolarizing NMB agents with intermediate teaching Hospital in Iran. duration of action 1. Cisatracurium besilate is the MATERIALS AND METHODS : A cost analysis R-cis isomer of atracurium besilate and is 3-4 fold and adverse drug reactions (ADR) monitoring more potent than atracurium 3. Compared with were performed. Only direct costs were consid - ered and data were collected through a prospec - atracurium, cisatracurium besilate was associated tive randomized study. Regardless of the type of with a lower tendency to cause histamine release 4 surgery, 100 patients were randomly divided into and has a longer onset time at equal doses . In fact two equal groups to receive either cisatracurium the most disadvantage of atracurium is hemody - or atracurium by anesthesiologists. ADRs preva - namic instability, particularly in patients with car - lence and cost differences between patients re - diovascular problems or who have neurosurgery ceiving one of the two non-depolarizing NMB 1,4,5 agents were evaluated by independent sample t- or staying at Intensive Care unit (ICU) . Except test and Chi-square test respectively. this difference, according to literature, most of RESULTS : No significant difference was ob - other characteristics of both drugs are similar. served between the two groups of patients in de - The main objective of this study is to evaluate mographic data. There was no statistical differ - the economic and adverse drug reactions preva - ence in the ADR prevalence in both groups. The lence and differences between the two non-depolar - numbers of ADR within atracurium group was higher than cisatracurium group, but this distinc - izing neuromuscular blocking drugs, which are tion was not statistically significant ( p > 0.05). It widely used in adult patients undergoing surgery was significant difference in cost between the with general anesthesia in a teaching Hospital. two neuromuscular blocking drugs ( p < 0.05). CONCLUSIONS: According to our study it seems that atracurium and cisatracurium had similar safe - ty profile and atracurium had a cost benefit relative Materials and Methods to cisatracurium in initial loading doses. In patients with instability in hemodynamic parameters the cisatracurium was the appropriate choice. A prospective randomized study was de - signed to comparing adverse drug reactions Key Words: (ADR) and cost analysis between two popular Cisatracurium besilate, Atracurium besilate, Non- ® depolarizing neuromuscular blocking agents, General NMB agents, atracurium (Tracrium ) and anesthesia. cisatracurium (Nimbex ®) in patients undergoing elective surgery at Shariati Hospital in Tehran. Corresponding Author: Mohammadreza Javadi, BCPS; e-mail: [email protected] 447 A. Movafegh, S. Amini, H. Sharifnia, H. Torkamandi, A. Hayatshahi, M. Javadi Shariati Hospital is one of the Tehran Universi - Results ty Medical Science affiliated hospitals which provides variety procedures. One hundred subjects were enrolled in this Pre-anesthetic form was used to collect pa - study. The patients within two groups had similar tients’ demographic data (gender, age, and demographic data (p > 0.05). There was no signifi - weight, etc.). For monitoring and evaluating ad - cant difference in weight, age or gender in be - verse drug reactions causing by NMB agents, tween the cisatracurium group (n=50) and the major therapeutic references were checked and atracurium group (n=50) (Table I). Chi-square test then the ADR form was made and used to collect was used for comparison of side effects of information on all side effects. atracurium and cis atracurium. The ADR findings Investigators, who evaluated adverse drug ef - related to NMB drugs are summarized in Table II. fects, were kept blinded of drug identity but anes - In spite of more hypotension occurrence in thesiologists were aware of specific NMB drug. atracurium group, there was no statistical differ - Regardless of the type of surgery, between Febru - ence in the ADR prevalence in both groups. The ary and August 2010, 100 patients were randomly numbers of ADR within atracurium group was divided into two equal groups to receive either higher than cisatracurium group, but this distinc - cisatracurium (0.15 mg/kg) (Group 1) or atracuri - tion was not statistically significant (p > 0.05). um (0.6 mg/kg) (Group 2) by anesthesiologists. For comparing the cost, mean dosage adminis - General anesthesia was induced with intravenous trated and unit drug cost was calculated. Based on propofol 2 nmg/kg and 3 mcg/kg sufentanil. the estimation the mean dosage used in the Anesthesia during surgery was maintained with atracurium group was 83.06±6.74 mg (mean±SD) infusion of 5 mcg sufentanil every 30 minute and and 21.01±2.43 mg (mean±SD) in the cisatracuri - isoflurane 1.5 to 2%. The patients were recovered um group. The cost calculations showed that mean from the block with administrating neostigmine costs were $8.64±1.10, and $16.63±2.71 for (50 mcg/kg) and atropine (15 mcg/kg ). atracurium and cisatracurium respectively (Table For each patient the ADR monitoring was per - III). It was significant difference in cost between formed and ADR form was completed. To com - the two NMB drugs (p < 0.05). pare the demographic characteristics of the groups, independent sample t-test was per - formed. The chi-square test was used to compare Discussion adverse drug reactions types and frequencies. All data were expressed as means ± SD. There are some important points when com - In order to evaluate the impact of drug costs, paring two anesthetic drugs including adverse we compared the price differences between two drug reactions, drug safety profiles and cost 4. groups. For as much as neuromuscular blocking In our Hospital ordering and the prescription drug was administered as milligrams per kilo - of cisatracurium was dramatically more than gram we evaluated the mean dosage of the used atracurium. Most anesthesiologists at our Hospi - drugs and then, the cost of drugs was calculated. tal believed that cisatracurium complications less The results was analyzed with independent sam - than atracurium occurred. Hence , we designed ple t-test and reported as mean ± SD. p < 0.05 this study for comparing ADRs and cost analysis was considered statistically significant. in between these two drugs. Table I. Demographic information and two groups analogous test. All patients Atracurium Cisatracurium p-value Number of patients (n) 100 50 50 1.000 Gender (n, %) Male 45.45.0% 21.42.0% 24.48.0% 0.551 Female 55.55.0% 29.58.0% 26.52.0% Age (yr) mean ± SD 47 ± 16 43 ± 11 45 ± 14 0.153 Weight (kg) mean ± SD 69.6 ± 13.9 69.2 ± 11.2 70.0 ± 16.2 0.769 448 Cost analysis and safety comparison of Cisatracurium and Atracurium Table II. Comparison of two groups in adverse drug reaction. Adverse drug reaction Atracurium Cisatracurium p-value Cardiovascular – n (%) Bradycardia 2 (4.0%) 0 0.159 Tachycardia 6 (12.0%) 4 (8.0%) 0.510 Hypertension 2 (4.0%) 1 (2.0%) 0.562 Hypotension 7 (14.0%) 0 0.007 Flushing 2 (4.0%) 0 0.159 Collapse 00– Respiratory – n (%) Hyperthermia 00– Wheezing 3 (6.0%) 1 (2.0%) 0.313 Bronchial secretion 1 (2.0%) 1 (2.0%) 1.000 Bronchospasm 2 (4.0%) 1 (2.0%) 0.562 Laryngospasm 00– Dyspnea 00– Apnea 00– Skin – n (%) Erythema 9 (18.0%) 4 (8.0%) 0.140 Itching 0 1 (2.0%) 0.322 Urticaria 6 (12.0%) 1 (2.0%) 0.052 Muscle – n (%) Acute quadriplegic myopathy syndrome 00– Myositis ossificans 00– Other – n (%) Seizure 00– Prolong recovery time 00– Injection reaction 5 (10.0%) 1 (2.0%) 0.098 In this study, for both drugs, adverse drug re - with atracurium. By calculating the mean drugs actions and drug safety profiles are the same. required for each group cisatracurium became Differences between adverse reactions of these the most expensive and atracurium the least ex - drugs, (atracurium and cisatracurium) statistical - pensive agent. As it was mentioned before, safe - ly are negligible. Therefore , safety profiles of ty profiles of both drugs are similar. Therefore , both drugs are similar in accordance with author - indirect effecting factors such as the cost of de - itative drug references. Consequently, third item layed recovery and treatment of adverse effects (cost) is the governing factor in this comparison. were negligible. In such case, it is recommended to use the more Usually , 5 percent of patient’s charges are re - inexpensive alternative 6. lated to anesthetic drugs and 30 percent of this Drug usage was converted to cost by multiply - cost is related to neuromuscular blocking ing “drug usage in mg per kg” by “drug cost” in agents 7,8 .
Load more

Recommended publications
  • A Comparative Study of Neuromuscular Blocking Effects
    IndianJournalofAnesthesiaandAnalgesia OriginalResearchArticle January–February2020;7(1)(Part-I):58-63 DOI:http://dx.doi.org/10.21088/ijaa.2349.8471.7120.9 AComparativeStudyofNeuromuscularBlockingEffectsandReversibility ofCisatracuriumandVecuronium DivyaNKheskani1,HeenaSChhanwal2,BhaktiSJain3 1AssistantProfessor,2ProfessorandHead,3rdYearResident,DepartmentofAnaesthesia,GCSMedicalCollege,Hospital&Research Centre,NearChamundaBridge,Ahmedabad,Gujarat380025,India. Abstract Context: Cisatracurium is a cis isomer of parent compound atracurium, devoid of histamine release, thus possessing hemodynamic & cardiovascular stability. Aims: We compared the intubating conditions, hemodynamic stability & recovery of atracurium & vecuronium. Settings and Design: We carried out prospective, double blind randomized study after approval of ethical committee. 100 adult patients of ASA 1 &2with comparable demographicdatawereselected. Dividedin TwoGroupsC(Cisatracurium) &V(Vecuronium).Standardmonitoringwasdone&followingroutinepremedication&inductionagents, patientswereintubatedat2minsafteradministrationofcisatracurium0.15mg/kg&vecuronium0.1mg/ kgrespectively,maintainedonintermittentdoseofcisatracurium:0.03mg/kg&vecuronium:0.02mg/kg. IntubationconditionswereassessedaccordingtoTimeto25%recoveryoft1/tcfollowinginitialdoses,Time to25%recoveryoft1/tcfollowingrepeatedboluses,Timeto25%recoveryoft1/tcfollowinglastdose,Return oft4/t1ratio0.8spontaneousrecoveryatendofoperation.Statisticalanalysisused:Theresultswereevaluated byapplyingpairedt-testandp-valueusingSPSSStatisticalSoftware.Results:Intubatingconditionsat2mins
    [Show full text]
  • The Study Programme for the Quality Management of Essential Medicines - Good Manufacturing Practical (GMP) and Inspection
    The Study Programme for the Quality Management of Essential Medicines - Good Manufacturing Practical (GMP) and Inspection - Country Reports Japan International Corporation of Welfare Services (JICWELS) Contents 1. Cambodia 1 2. Indonesia 70 3. Malaysia 91 4. Philippines 116 5. Sri Lanka 141 6. Thailand 161 The Study Programme for the Quality Management of Essential Medicines - Good Manufacturing Practical (GMP) and Inspection - Cambodia -1- KINGDOM OF CAMBODIA Nation Religion King Ministry of Health Department of Drugs and Food Country Report The Study Program on Quality Management of Essential Medicines Good Manufacturing Practice (GMP) and Inspection November 4, 2012 – November 30, 2012 Sponsored by : The Government of Japan Japan International Cooperation Agency (JICA) Department of Drugs and Food Ministry of Health, Cambodia. -2- I- COUNTRY PROFILE -3- A-Geography Cambodia is an agricultural country located in South East Asia which bordering the Gulf of Thailand, between Thailand, Vietnam, and Laos. Its approximate geographical coordinates are 13°N 105°E. Its 2,572 km border is split among Vietnam (1,228 km), Thailand (803 km) and Laos (541 km), as well as 443 km of coastline. Cambodia covers 181,035 square kilometers in the southwestern part of the Indochina, Cambodia lies completely within the tropics; its southernmost points are only slightly more than 10° above the equator. The country is bounded on the north by Thailand and by Laos, on the east and southeast by Vietnam, and on the west by the Gulf of Thailand and by Thailand. It consists of the Tonle Sap Basin and the Mekong Lowlands. To the southeast of this great basin is the Mekong Delta, which extends through Vietnam to the South China Sea.
    [Show full text]
  • Etats Rapides
    List of European Pharmacopoeia Reference Standards Effective from 2015/12/24 Order Reference Standard Batch n° Quantity Sale Information Monograph Leaflet Storage Price Code per vial Unit Y0001756 Exemestane for system suitability 1 10 mg 1 2766 Yes +5°C ± 3°C 79 ! Y0001561 Abacavir sulfate 1 20 mg 1 2589 Yes +5°C ± 3°C 79 ! Y0001552 Abacavir for peak identification 1 10 mg 1 2589 Yes +5°C ± 3°C 79 ! Y0001551 Abacavir for system suitability 1 10 mg 1 2589 Yes +5°C ± 3°C 79 ! Y0000055 Acamprosate calcium - reference spectrum 1 n/a 1 1585 79 ! Y0000116 Acamprosate impurity A 1 50 mg 1 3-aminopropane-1-sulphonic acid 1585 Yes +5°C ± 3°C 79 ! Y0000500 Acarbose 3 100 mg 1 See leaflet ; Batch 2 is valid until 31 August 2015 2089 Yes +5°C ± 3°C 79 ! Y0000354 Acarbose for identification 1 10 mg 1 2089 Yes +5°C ± 3°C 79 ! Y0000427 Acarbose for peak identification 3 20 mg 1 Batch 2 is valid until 31 January 2015 2089 Yes +5°C ± 3°C 79 ! A0040000 Acebutolol hydrochloride 1 50 mg 1 0871 Yes +5°C ± 3°C 79 ! Y0000359 Acebutolol impurity B 2 10 mg 1 -[3-acetyl-4-[(2RS)-2-hydroxy-3-[(1-methylethyl)amino] propoxy]phenyl] 0871 Yes +5°C ± 3°C 79 ! acetamide (diacetolol) Y0000127 Acebutolol impurity C 1 20 mg 1 N-(3-acetyl-4-hydroxyphenyl)butanamide 0871 Yes +5°C ± 3°C 79 ! Y0000128 Acebutolol impurity I 2 0.004 mg 1 N-[3-acetyl-4-[(2RS)-3-(ethylamino)-2-hydroxypropoxy]phenyl] 0871 Yes +5°C ± 3°C 79 ! butanamide Y0000056 Aceclofenac - reference spectrum 1 n/a 1 1281 79 ! Y0000085 Aceclofenac impurity F 2 15 mg 1 benzyl[[[2-[(2,6-dichlorophenyl)amino]phenyl]acetyl]oxy]acetate
    [Show full text]
  • (12) Patent Application Publication (10) Pub. No.: US 2006/0024365A1 Vaya Et Al
    US 2006.0024.365A1 (19) United States (12) Patent Application Publication (10) Pub. No.: US 2006/0024365A1 Vaya et al. (43) Pub. Date: Feb. 2, 2006 (54) NOVEL DOSAGE FORM (30) Foreign Application Priority Data (76) Inventors: Navin Vaya, Gujarat (IN); Rajesh Aug. 5, 2002 (IN)................................. 699/MUM/2002 Singh Karan, Gujarat (IN); Sunil Aug. 5, 2002 (IN). ... 697/MUM/2002 Sadanand, Gujarat (IN); Vinod Kumar Jan. 22, 2003 (IN)................................... 80/MUM/2003 Gupta, Gujarat (IN) Jan. 22, 2003 (IN)................................... 82/MUM/2003 Correspondence Address: Publication Classification HEDMAN & COSTIGAN P.C. (51) Int. Cl. 1185 AVENUE OF THE AMERICAS A6IK 9/22 (2006.01) NEW YORK, NY 10036 (US) (52) U.S. Cl. .............................................................. 424/468 (22) Filed: May 19, 2005 A dosage form comprising of a high dose, high Solubility active ingredient as modified release and a low dose active ingredient as immediate release where the weight ratio of Related U.S. Application Data immediate release active ingredient and modified release active ingredient is from 1:10 to 1:15000 and the weight of (63) Continuation-in-part of application No. 10/630,446, modified release active ingredient per unit is from 500 mg to filed on Jul. 29, 2003. 1500 mg, a process for preparing the dosage form. Patent Application Publication Feb. 2, 2006 Sheet 1 of 10 US 2006/0024.365A1 FIGURE 1 FIGURE 2 FIGURE 3 Patent Application Publication Feb. 2, 2006 Sheet 2 of 10 US 2006/0024.365A1 FIGURE 4 (a) 7 FIGURE 4 (b) Patent Application Publication Feb. 2, 2006 Sheet 3 of 10 US 2006/0024.365 A1 FIGURE 5 100 ov -- 60 40 20 C 2 4.
    [Show full text]
  • Observations on the Use of Different Modes of Cisatracurium Administration in Hyperthermic Intraperitoneal Chemotherapy
    Observations on the Use of Different Modes of Cisatracurium Administration in Hyperthermic Intraperitoneal Chemotherapy Jing Zhang Capital Medical University Aliated Beijing Shijitan Hospital Danyang Gao Capital Medical University Aliated Beijing Shijitan Hospital https://orcid.org/0000-0002-8491-5376 Pengfei Liu Capital Medical University Aliated Beijing Shijitan Hospital Tianzuo Li ( [email protected] ) Capital Medical University Aliated Beijing Shijitan Hospital Research Article Keywords: Cis-atracurium, Intraperitoneal hyperperfusion chemotherapy (HIPEC), Anesthesia, Residual muscle relaxation Posted Date: April 12th, 2021 DOI: https://doi.org/10.21203/rs.3.rs-392323/v1 License: This work is licensed under a Creative Commons Attribution 4.0 International License. Read Full License Page 1/10 Abstract Objective: To investigate the residual effects of cis-atracurium with different administrations in patients with hyperthermic intraperitoneal chemotherapy. Methods: 60 patients undergoing hyperthermic intraperitoneal chemotherapy were randomly divided into two groups with 30 cases in each group. All patients were induced with sufentanil 0.4ug/kg, propofol 2.0mg/kg and cis atracurium 0.2mg/kg. During the operation, sevourane and remifentanil were used to maintain anesthesia. BIS value was 45-55. The control group intermittently received cis-atracurium injection with 0.1mg/kg/h. The experimental group received continuous injection of cis-atracurium at a rate of 1.5ug/kg/min. Cis-atracurium was discontinued 30min before the end of the operation, sevourane inhalation was stopped 20min before the end of the surgery and remifentanil was discontinued 10min before the end. At the end of the operation, no muscle relaxant antagonism were applied. General information of patients was recorded.
    [Show full text]
  • The New Neuromuscular Blocking Agents: Do They Offer Any Advantages?
    British Journal of Anaesthesia 87 (6): 912±25 (2001) REVIEW ARTICLE The new neuromuscular blocking agents: do they offer any advantages? E. W. Moore* and J. M. Hunter² University Department of Anaesthesia, University Clinical Department, The Duncan Building, Daulby Street, Liverpool L69 3GA, UK *Corresponding author Br J Anaesth 2001; 87: 912±25 Keywords: neuromuscular block, aminosteroids; neuromuscular block, benzylisoquinoliniums; neuromuscular block, tropinyl diesters; neuromuscular block, tetrahydroisoquinolinium chlorofumarates The introduction of neuromuscular blocking drugs in 1942 animal and human studies. The bis-quaternary ammonium marked a new era in anaesthetic and surgical practice. The salt of bistropinyl diester G-1-64 is the most studied of the anaesthetist was enabled to provide respiratory support tropinyl diester group51 although investigations in humans during long and complex surgery whilst the surgeon was have yet to be reported (Fig. 3). allowed access to body cavities without voluntary or re¯ex muscle movement. In recent years, a generation of anaesthetists trained since atracurium and vecuronium GW280430A became available in 1982, have taken for granted the The structure of this mixed-tetrahydroisoquinolinium speed of onset, shorter and more predictable duration of chlorofumarate is given in Figure 2. The similarity in action, and lack of cardiovascular side-effects that these structure to mivacurium is demonstrated. The presence of drugs have in comparison with their predecessors.56 58 59 three methyl groups between the quaternary nitrogen and The latest generation of neuromuscular blocking drugs aims oxygen atom at each end of the carbon chain suggests that, to provide even greater advantages: as rapid an onset and similar to mivacurium, this compound will not undergo offset as succinylcholine; disposition independent of organ Hofmann degradation.
    [Show full text]
  • Pharmaceutical Appendix to the Harmonized Tariff Schedule
    Harmonized Tariff Schedule of the United States Basic Revision 3 (2021) Annotated for Statistical Reporting Purposes PHARMACEUTICAL APPENDIX TO THE HARMONIZED TARIFF SCHEDULE Harmonized Tariff Schedule of the United States Basic Revision 3 (2021) Annotated for Statistical Reporting Purposes PHARMACEUTICAL APPENDIX TO THE TARIFF SCHEDULE 2 Table 1. This table enumerates products described by International Non-proprietary Names INN which shall be entered free of duty under general note 13 to the tariff schedule. The Chemical Abstracts Service CAS registry numbers also set forth in this table are included to assist in the identification of the products concerned. For purposes of the tariff schedule, any references to a product enumerated in this table includes such product by whatever name known.
    [Show full text]
  • EUROPEAN PHARMACOPOEIA 10.0 Index 1. General Notices
    EUROPEAN PHARMACOPOEIA 10.0 Index 1. General notices......................................................................... 3 2.2.66. Detection and measurement of radioactivity........... 119 2.1. Apparatus ............................................................................. 15 2.2.7. Optical rotation................................................................ 26 2.1.1. Droppers ........................................................................... 15 2.2.8. Viscosity ............................................................................ 27 2.1.2. Comparative table of porosity of sintered-glass filters.. 15 2.2.9. Capillary viscometer method ......................................... 27 2.1.3. Ultraviolet ray lamps for analytical purposes............... 15 2.3. Identification...................................................................... 129 2.1.4. Sieves ................................................................................. 16 2.3.1. Identification reactions of ions and functional 2.1.5. Tubes for comparative tests ............................................ 17 groups ...................................................................................... 129 2.1.6. Gas detector tubes............................................................ 17 2.3.2. Identification of fatty oils by thin-layer 2.2. Physical and physico-chemical methods.......................... 21 chromatography...................................................................... 132 2.2.1. Clarity and degree of opalescence of
    [Show full text]
  • Anticancer Effects of Vecuronium Bromide and Cisatracurium Besylate
    G Model BIOMAG-154; No. of Pages 5 ARTICLE IN PRESS Biomedicine & Aging Pathology xxx (2014) xxx–xxx Available online at ScienceDirect www.sciencedirect.com Original article Anticancer effects of vecuronium bromide and cisatracurium besylate on lung cancer cells (A549), in vitro a b,e c Iddrisu Baba Yabasin , Mohammed Mohammed Ibrahim , Abass Adam , d e a Sam-Awortwi Wilfred , Juventus Benogle Ziem , Peng Gao , f a,∗ Silvanus Kampo , Wen Qingping a Department of Anesthesiology, Dalian Medical University, 9 Western Section, Lvshun South Road, 116044 Dalian Liaoning, PR China b Department of Pathology and Pathophysiology, Dalian Medical University, 9 Western Section, Lvshun South Road, 116044 Dalian Liaoning, PR China c Department of Surgical Sciences, School of Medicine & Health Sciences, University for Development Studies, Box 1350, Tamale, Ghana d Department of Anesthesia, Komfo Anokye Teaching Hospital, Box 1934, Kumasi, Ghana e Department of Laboratory Science, School of Medicine & Health Sciences, University for Development Studies, Box 1350, Tamale, Ghana f Department of Anesthesia, School of Medicine & Health Sciences, University for Development Studies, Box 1350, Tamale, Ghana a r t i c l e i n f o a b s t r a c t Article history: Neuromuscular blocking drugs are used in anesthesia and intensive care to provide skeletal muscle relax- Received 10 April 2014 ation. However, literature has revealed that the effects of these drugs on cancer have not been widely Accepted 10 July 2014 studied. We tested the effects of two non-depolarising neuromuscular blocking drugs, vecuronium bro- Available online xxx mide and cisatracurium besylate on lung cancer cells’ (A549) proliferation, migration and viability in the presence of a cytotoxic drug, cisplatin.
    [Show full text]
  • Summary of Product Characteristics
    SUMMARY OF PRODUCT CHARACTERISTICS 1. NAME OF THE MEDICINAL PRODUCT Cisatracurium Strides 2 mg/ml solution for injection/infusion Cisatracurium Strides 5 mg/ml solution for injection/infusion Cisatracurium Strides 10 mg/ml solution for injection/infusion 2. QUALITATIVE AND QUANTITATIVE COMPOSITION 2 mg/ml 1 ml solution for injection/infusion contains Cisatracurium 2 mg as Cisatracurium besilate 2.68 mg. One vial of 5 ml solution contains 10 mg of Cisatracurium as Cisatracurium besilate. 5 mg/ml 1 ml solution for injection/infusion contains Cisatracurium 5 mg as Cisatracurium besilate 6.70 mg. One vial of 30 ml solution contains 150 mg of Cisatracurium as Cisatracurium besilate. 10 mg/ml 1 ml solution for injection/infusion contains Cisatracurium 10 mg as Cisatracurium besilate13.40 mg. One vial of 20 ml solution contains 200 mg of Cisatracurium as Cisatracurium besilate. For the full list of excipients, see section 6.1. 3. PHARMACEUTICAL FORM Solution for injection/infusion Colourless to slightly yellow or greenish yellow solution. Practically free from visible particulate matter. pH: 3.0-3.8 4. CLINICAL PARTICULARS Cisatracurium Strides is an intermediate-duration, non-depolarising neuromuscular blocking agent for intravenous administration 4.1 Therapeutic indications 1 AT/H/0432/001-003/DC, REVISED final SmPC Cisatracurium Strides is indicated for use during surgical and other procedures and in intensive care in adults and children aged 1 month and over. Cisatracurium Strides can be used as an adjunct to general anaesthesia, or sedation in the Intensive Care Unit (ICU) to relax skeletal muscles, and to facilitate tracheal intubation and mechanical ventilation.
    [Show full text]
  • Texts Adopted by the European Phamacopoeia Commission
    © Pharmeuropa | Useful information | June 2015 1 List of texts adopted at the March 2015 session of the European Pharmacopoeia Commission NEW TEXTS GENERAL CHAPTERS 2.5.41. Methyl, ethyl and isopropyl benzenesulfonate in active substances 2.7.34. Assay of human C1-esterase inhibitor 5.19. Extemporaneous preparation of radiopharmaceuticals 5.21. Chemometric methods applied to analytical data MONOGRAPHS Vaccines for human use Haemophilus type b and meningococcal group C conjugate vaccine (2622) Radiopharmaceutical preparations and starting materials for radiopharmaceutical preparations Technetium (99mTc) oxidronate injection (2376) Herbal drugs and herbal drug preparations Aucklandia root (1797) Homoeopathic preparations Acidum picrinicum for homoeopathic preparations (2695) Histaminum for homoeopathic preparations (2671) Monographs Cisatracurium besilate (2763) Dienogest (2732) Entecavir monohydrate (2815) Gadobutrol monohydrate (2735) Gefitinib (2866) Human C1-esterase inhibitor (2818) Hydroxypropylcellulose, low-substituted (2083) Pregabalin (2777) Rabeprazole sodium (2868) 2 © Pharmeuropa | Useful information | June 2015 Rabeprazole sodium hydrate (2331) Ropinirole hydrochloride (2604) Sitagliptin phosphate monohydrate (2778) Sitagliptin tablets (2927) Sodium lauroylsarcosinate for external use (2542) Thiocolchicoside crystallised from ethanol (2896) Thiocolchicoside hydrate (2814) REVISED TEXTS GENERAL CHAPTERS 2.2.31. Electrophoresis 2.2.48. Raman spectroscopy 2.5.38. Methyl, ethyl and isopropyl methanesulfonate in active substances
    [Show full text]
  • Comparative Study of Atracurium and Cisatracurium for Intubating Conditions Under General Anaesthesia
    IOSR Journal of Dental and Medical Sciences (IOSR-JDMS) e-ISSN: 2279-0853, p-ISSN: 2279-0861.Volume 19, Issue 2 Ser.17 (February. 2020), PP 52-56 www.iosrjournals.org Comparative study of Atracurium and cisatracurium for intubating conditions under general anaesthesia 1 2 Dr. Mitali KhobragadeN , Dr Rajashri B. Sonwane Senior resident Department of Anaesthesiology Government medical College Aurangabad Associate Professor Department of Anaesthesiology Government Medical College Aurangabad Corresponding author: Dr Rajashri B Sonwane Abstract: Introduction: Good intubating conditions minimizes the risk of trauma associated with tracheal intubation. Atracurium and cisatracurium, non depolarising muscle relaxant can be used to facilitate intubation. Aims and Objectives:To compare the intubating conditions of atracurium and cisatracurium Material and Methods: 60 patients randomized into 2 groups of 30 each.Group A received inj atracurium 0.5mg/kg and Group B received cisatracurium 0.15mg/kg for intubation . Laryngoscopic grading, number of intubation attempts, time taken for intubation, haemodynamic parameters and signs of histamine release were observed. Results: In 50% patients of Group A & 100% patients in Group B the laryngoscopic grading was I i.e. excellent & 50% in Group A laryngoscopic grading was grade II i.e. good. All patients in both groups intubated in first atempt .Time taken for intubation was statistically significant (Group A 58.33-+5.4 secs ,Group B 42.40+ 10.70 secs,P<0.005),. Haemodynamic parameters were comparable in both
    [Show full text]